Cellular senescence—the process where cells stop dividing and accumulate with age—is considered a hallmark of biological aging. These senescent cells release harmful molecules (the senescence-associated secretory phenotype, or SASP) that can spread damage to neighboring tissues and drive disease. Current methods to measure senescence burden are impractical for clinical use, creating a gap between aging research and real-world application.
The researchers tackled this by developing a 'SASP Score'—a composite biomarker derived from blood proteins associated with senescence. They trained a deep learning model (Guided autoencoder with Transformer, or GAET) on proteomics data from the UK Biobank's Pharma Proteomics Project, identifying which blood proteins best capture senescent cell burden. They then tested this score in the same UK Biobank cohort and validated it in an independent randomized controlled trial that included an exercise intervention.
The results are promising: the SASP Score independently predicted mortality and incident serious chronic diseases (dementia, COPD, myocardial infarction, stroke) even after adjusting for traditional risk factors. Notably, in the intervention cohort, multimodal exercise (combining aerobic, resistance, and flexibility training) significantly altered the SASP Score trajectory over 18 months, suggesting the biomarker is responsive to lifestyle changes.
However, this is a preprint on medRxiv, meaning it has not yet undergone peer review—a critical gatekeeping step in science. The paper lacks detail on several important points: exact sample sizes for each analysis, effect sizes with confidence intervals, and specifics about the independent validation cohort. The cross-sectional associations within UK Biobank could reflect reverse causality (sick people have more senescent cells, not the reverse). The exercise study is interesting but relatively small and short-term; we don't yet know if the SASP Score changes persist, whether they predict real health improvements, or how durable the intervention effects are.
This work is methodologically sound and uses credible data sources, but the evidence is preliminary. The SASP Score could become a valuable tool for aging research and personalized medicine, but it needs peer-reviewed publication, independent replication, and longer follow-up studies before clinical adoption. It's a promising direction, not yet a proven solution.
0 Comments
Log in to join the discussion.